ArticleScientific reports2025
One step synthesis of Ag nanoparticles incorporated PVA nanocomposite via plasma reduction route.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Green solution-plasma synthesis of GO-Ag nanocomposites for ultrasensitive SERS detection of rhodamine B and synergistic antibacterial activity.RSC advances · 2026Article
- Multifunctional PVA-CMC/ZnO-Au Nanocomposite Films with Enhanced UV Shielding, Thermal Stability, and Antibacterial Performance.Polymers · 2026Article
- A Flexible, Antibacterial Platform: Silver-Tuned Polyvinyl Alcohol with Enhanced Opto-Mechanical and Electrical Properties.Polymers · 2026Article
- Green tea dye ligands to transfer toxic lead metal ions to precipitated metal complexes for polymer composite applications.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PVA/Ag nanocomposite films were synthesized via a one-step plasma-solution reduction method with varying processing times. Following synthesis, the PVA/Ag NP solutions were cast to form films, which were subsequently characterized by TEM, XRD, FTIR, XPS, UV-Vis, and Raman spectroscopy. Antimicrobial activity was evaluated using an agar diffusion test. TEM analysis confirmed the presence of Ag NPs with diverse sizes and shapes, averaging around 16.1 nm. XRD analysis showed a distinct peak at 2θ = 38°, corresponding to the Ag (111) plane in films synthesized at 10, 15, and 20 min, indicating the formation of crystalline Ag NPs. XPS results demonstrated an increased O/C ratio in plasma-synthesized PVA/Ag nanocomposite films, along with a new peak at 369.15 eV attributed to the Ag 3d orbital, confirming the presence of Ag NPs within the PVA matrix. FTIR spectra further suggested the formation of coordinate bonds between Ag NPs and PVA polymer chains. UV-Vis analysis revealed a localized surface plasmon resonance (LSPR) peak at approximately 425 nm, with a redshift to 445 nm at a longer processing time (20 min). This suggests alterations in NP size or interaction with the matrix. The optical bandgap of PVA/AgNP films decreased with longer plasma processing time, accompanied by increased film opacity. Raman analysis highlighted the potential use of PVA/Ag NP films (synthesized at 5 min) as substrates for surface-enhanced Raman spectroscopy (SERS). The PVA/Ag NP composite synthesized at a plasma processing time of 20 min exhibited considerable antibacterial activity against S. aureus and C. albicans. Also, the percentage of biofilm inhibition of S. aureus was 65%, compared to the control. Collectively, these findings suggest that plasma-synthesized PVA/Ag NP nanocomposite films are promising candidates for various applications, including optical devices, food packaging, SERS, and wound dressings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.